Jiangsu Bioperfectus Technologies Co., Ltd. (SHA:688399)
China · Delayed Price · Currency is CNY 67.51
-0.09 (-0.13%)
At close: Feb 13, 2026
SHA:688399 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 320.78 | 331.36 | 380.05 | 4,336 | 2,340 | 1,505 |
Other Revenue | 18.25 | 18.25 | 23.13 | 1,199 | 499.11 | 235.03 |
| 339.03 | 349.61 | 403.18 | 5,535 | 2,839 | 1,740 | |
Revenue Growth (YoY) | -14.13% | -13.29% | -92.72% | 94.95% | 63.19% | 502.39% |
Cost of Revenue | 150.31 | 147.64 | 253.94 | 2,380 | 879.96 | 390.72 |
Gross Profit | 188.72 | 201.97 | 149.24 | 3,155 | 1,959 | 1,349 |
Selling, General & Admin | 202.05 | 214.27 | 377.62 | 720.25 | 534.41 | 366.2 |
Research & Development | 89.38 | 100.52 | 135.39 | 185.32 | 106.35 | 70.36 |
Other Operating Expenses | 23.89 | -7.42 | -8.87 | 17.48 | -5.25 | -5.03 |
Operating Expenses | 297.58 | 270.92 | 533.52 | 981.87 | 648.43 | 437.99 |
Operating Income | -108.86 | -68.95 | -384.28 | 2,173 | 1,311 | 910.97 |
Interest Expense | -8.01 | -7.75 | -6.94 | -5.33 | -3.96 | -0.08 |
Interest & Investment Income | 25.21 | 39.78 | 57.56 | 42.74 | 26.83 | 7.77 |
Earnings From Equity Investments | - | - | - | - | -2.74 | -0.69 |
Currency Exchange Gain (Loss) | 1.1 | 1.1 | -1.19 | 0.76 | -1.53 | -1.54 |
Other Non Operating Income (Expenses) | 1.65 | -0.49 | -0.16 | -0.33 | -3.33 | -0.26 |
EBT Excluding Unusual Items | -88.91 | -36.31 | -335.02 | 2,211 | 1,326 | 916.16 |
Gain (Loss) on Sale of Investments | 39.94 | 0.83 | 13.12 | 48.15 | 32.19 | 19.94 |
Gain (Loss) on Sale of Assets | 0.03 | 2.07 | -2.92 | -1.44 | 2.97 | 4.56 |
Asset Writedown | -18.91 | -9.33 | -79.01 | -140.31 | - | - |
Other Unusual Items | 46.93 | 46.93 | 28.16 | 21.76 | 30.72 | 20.33 |
Pretax Income | -20.92 | 4.19 | -375.67 | 2,139 | 1,392 | 960.99 |
Income Tax Expense | 5.04 | 6.19 | -1.86 | 310.81 | 198.56 | 141.42 |
Net Income | -25.96 | -2 | -373.81 | 1,828 | 1,193 | 819.57 |
Net Income to Common | -25.96 | -2 | -373.81 | 1,828 | 1,193 | 819.57 |
Net Income Growth | - | - | - | 53.19% | 45.59% | 878.52% |
Shares Outstanding (Basic) | 92 | 99 | 87 | 87 | 87 | 87 |
Shares Outstanding (Diluted) | 92 | 99 | 87 | 87 | 87 | 87 |
Shares Change (YoY) | 5.63% | 13.71% | -0.06% | 0.03% | -0.03% | 29.48% |
EPS (Basic) | -0.28 | -0.02 | -4.31 | 21.07 | 13.76 | 9.45 |
EPS (Diluted) | -0.28 | -0.02 | -4.31 | 21.07 | 13.76 | 9.45 |
EPS Growth | - | - | - | 53.14% | 45.64% | 655.67% |
Free Cash Flow | 10.52 | 83.06 | -224.48 | 1,614 | 681.91 | 801.32 |
Free Cash Flow Per Share | 0.11 | 0.84 | -2.59 | 18.60 | 7.86 | 9.24 |
Dividend Per Share | 3.400 | - | - | - | 6.757 | 4.730 |
Dividend Growth | - | - | - | - | 42.86% | 366.67% |
Gross Margin | 55.66% | 57.77% | 37.02% | 56.99% | 69.01% | 77.54% |
Operating Margin | -32.11% | -19.72% | -95.31% | 39.26% | 46.16% | 52.36% |
Profit Margin | -7.66% | -0.57% | -92.72% | 33.03% | 42.03% | 47.11% |
Free Cash Flow Margin | 3.10% | 23.76% | -55.68% | 29.16% | 24.02% | 46.06% |
EBITDA | -74.06 | -19.59 | -315.5 | 2,256 | 1,344 | 933.05 |
EBITDA Margin | -21.85% | -5.60% | -78.25% | 40.76% | 47.35% | 53.63% |
D&A For EBITDA | 34.8 | 49.36 | 68.78 | 83.4 | 33.63 | 22.08 |
EBIT | -108.86 | -68.95 | -384.28 | 2,173 | 1,311 | 910.97 |
EBIT Margin | -32.11% | -19.72% | -95.31% | 39.26% | 46.16% | 52.36% |
Effective Tax Rate | - | 147.81% | - | 14.53% | 14.27% | 14.72% |
Revenue as Reported | 339.03 | 349.61 | 403.18 | 5,535 | 2,839 | 1,740 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.